Infinium Pharmachem opened lower at ₹312.00, compared with its previous close of ₹317.00. During today's session, the stock has traded between ₹302.00 and ₹312.00, with an average traded price of ₹304.42. It is currently showing a downward intraday trend.
return calculator
Time Period
An investment of ₹10,000 made 4 years ago in Infinium Pharmachem is now worth
₹ 11,311.00
giving a profit of
₹ 1,311.00 (13.11%)
invest now
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
-15.00 (-4.73%)
Day High
₹312.00
Day Low
₹302.00
Day Open
₹312.00
Prev Close
₹317.00
Volume
3,500
Value Traded
₹0.11 Cr
1W Return
-3.14%
1M Return
13.45%
3M Return
47.28%
6M Return
40.43%
1Y Return
17.74%
Fundamentals
Market Cap (₹ Cr.)
471
PE Ratio
34.80
PB Ratio
4.08
Dividend Yield
-
ROE
6.28%
ROCE
11.31%
Book Value (₹)
77.68
Face Value (₹)
10.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
Investment Returns
1 Week
-3.14%
6 Week
-
1 Month
13.45%
3 Month
47.28%
9 Month
41.20%
Financials
Yearly
Consolidated
All values in ₹ crores
0.71
Mar 21
1.00
Mar 22
1.16
Mar 23
1.37
Mar 24
1.58
Mar 25
1.90
Mar 26
Share Holding Pattern
Promoter64.91%
FII0.00%
DII0.22%
Retails & Others31.96%
Updates
24Jun
Infinium Pharmachem FY26 net profit rises 18% to ₹1215.02 lakh
Infinium Pharmachem reported an 18.3% rise in consolidated net profit to ₹1215.02 lakh for FY26, with revenue increasing to ₹18963.17 lakh. Standalone net profit grew to ₹1001.74 lakh. The Board approved the audited results and confirmed an unmodified auditor opinion.
3mo ago
21May
Infinium Pharmachem resumes Sojitra plant ops
Infinium Pharmachem received a Revocation Order from the Gujarat Pollution Control Board, lifting the earlier closure direction for its GIDC Sojitra facility. The company confirmed that manufacturing operations resumed on May 20, 2026, ensuring compliance with all conditions mentioned in the order.
4mo ago
16Jan
Infinium Pharmachem Launches New Manufacturing Plant for Contrast Media Raw Materials
Infinium Pharmachem has started operations at its new manufacturing plant for contrast media raw materials, targeting ₹100 crore in annual revenue. This facility expansion represents a strategic move to strengthen the company's position in the specialized pharmaceutical segment of contrast media production.
